We spoke with Charles Finsterwald, PhD, Chief Scientific Officer and co-founder of the start-up Gliapharm about his career path and his decision to switch from fundamental research to application. An interest in neuroscience After a bachelor in biology and a Read more…

According to WHO, more than 264 million people in the world suffer from depression, a disorder that has a major impact on all facets of the lives of those it affects. It became the first cause of invalidity in 2020. Read more…

Bipolar disorders affect some 2% of the population. Patients present a wide variety of clinical symptoms of which many can be especially handicapping. A new approach to find biomarkers, driven by Pascal Jourdain, could change the game by improving treatment Read more…

Pierre Marquet’s career path has been rather untypical. Combining qualifications in physics and psychiatry-psychotherapy, he is a clinical researcher “par excellence”, engaged for over 20 years in the development of knowledge about the biological dimensions of mental disorders. His career Read more…

Ryan Murray’s work within Synapsy WP#5 focuses on measuring brain reactivity to and recovery from psychosocial stress within clinical patients and healthy controls. He talked to us about his role as a psychologist in a clinical research group and his Read more…

Giorgio Pistis is profiling polygenic scores to understand whether genetic risks associated with particular pathophysiological pathways are higher in specific sub-groups of patients of the mood disorder cohort. Synapsy met him to find out more about his project. Giorgio Pistis Read more…

2020 has been a challenging year for the Synapsy community and for the whole society. The impact of the COVID-19 pandemic on health, economy and employment has been unprecedented worldwide. Like many other domains, science has been hit hardly by Read more…